Mohanakumari Naidu, MD
Psychiatry · Elgin, ILNPI 1861561292
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,911 and has fallen 54.0% since, to $879 in 2025. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$575
- Vanda Pharmaceuticals Inc.$418
- Tris Pharma Inc$303
- Johnson & Johnson$301
- Lundbeck LLC$261
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,102100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 65 | $1,184 |
| Otsuka America Pharmaceutical, Inc. | 39 | $575 |
| Vanda Pharmaceuticals Inc. | 18 | $418 |
| Tris Pharma Inc | 16 | $303 |
| Johnson & Johnson | 20 | $301 |
| Lundbeck LLC | 17 | $261 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $181 |
| Neos Therapeutics, LP | 9 | $176 |
| Neurocrine Biosciences, Inc. | 9 | $172 |
| AbbVie | 8 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $153 |
| Supernus Pharmaceuticals, Inc. | 8 | $141 |
| Teva Pharmaceuticals USA, Inc. | 7 | $138 |
| Corium, LLC | 9 | $134 |
| Alkermes, Inc. | 7 | $129 |
| E.r. Squibb & Sons, L.L.C. | 6 | $108 |
| Harmony Biosciences LLC | 4 | $88 |
| Ironshore Pharmaceuticals Inc. | 5 | $84 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Shire North American Group Inc | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Bausch Health US, LLC | 2 | $39 |
| Rhodes Pharmaceuticals L.p. | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $18 |
| Merck | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $13 |
| OWP Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$5,102 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 15 | $24,252 |
| Aripiprazole | 76 | $3,919 |
| Trazodone Hcl | 162 | $3,148 |
| Bupropion XlBupropion Hcl | 80 | $1,409 |
| Divalproex Sodium ErDivalproex Sodium | 54 | $1,306 |
| Buspirone Hcl | 52 | $1,181 |
| Quetiapine Fumarate | 140 | $1,136 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 40 | $1,135 |
| Lamotrigine | 138 | $1,062 |
| Escitalopram Oxalate | 109 | $1,032 |
| Alprazolam | 165 | $960 |
| Duloxetine Hcl | 88 | $887 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 103 | $868 |
| Doxepin Hcl | 28 | $842 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $181 | $24,25215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Elgin
- Syed WaliuddinElgin$32K
- Syed AnwarElgin$20K
- Michael FeldNorthbrook$1.1M
- Jose MontesRockford$882K
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Mark ShukhmanSkokie$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.